- As the government guides state re-openings, digital health startup BioIntelliSense announced the newest advancements of its medical-grade biosensor solution portfolio and Data-as-a-Service (DaaS) platform.
- The company’s new COVID-19 Return to Work and School solution generates a more reliable clinical assessment of an individual’s infectious risk status through home-based screening tools and data-driven clearance scores.
- The new BioButton™ is a single-use, coin-sized, disposable wearable medical device that continuously monitors COVID-related vital signs: temperature, respiratory rate at rest, and activity level for scalable enterprise workforce and student health deployments for 90 days.
BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced the advancement of its medical-grade biosensor product portfolio and Data-as-a-Service (DaaS) platform with the introduction of the BioButton™ device. The BioButton is a coin-sized, disposable medical device that measures continuous temperature and other vital signs for a remarkable 90-days.
BioIntelliSense offers medical-grade data services that allow for early detection of adverse trends through its proprietary biosensor technology and advanced analytics at a fraction of the cost of spot temperature measurements or traditional Remote Patient Monitoring (RPM) systems.
In combination, the new BioMobile self-monitoring smartphone app includes a consent-based survey tool for daily symptom checks and enterprise monitoring dashboard.
Together they make workforce and student monitoring of symptoms associated with COVID-19 reliable, effortless, and cost-effective. The platform can be applied to a wide range of COVID-19 related use cases for the monitoring of returning workforce and students, high-risk patient populations (including elderly, transplant, cancer, chronic conditions), COVID-19 patients in-hospital and in-home, and healthcare professionals.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“The introduction of the BioButton device, in combination with the BioMobile applications and enterprise triage dashboards, represents a significant advancement in making continuous medical-grade monitoring reliable, effortless and cost-effective,” said James Mault, MD, CEO of BioIntelliSense. “The convenience of the BioButton will support a range of clinical use cases for RPM reimbursement and mass market use to enable safe return to work or school.”
Availability
The new solution is now available for pre-orders for summer delivery.
Source: Hit Consultant
